Treatment is based on the differential characteristics of breast cancer subtypes and is largely successful in human epidermal growth factor receptor 2 (HER2) and estrogen receptor (ER) positive (luminal) cancers (using anti-HER2+ and hormonal therapies, respectively). Here, ERBB2 is linked to breast carcinoma.